Daniel Haggstrom

3.1k total citations · 1 hit paper
22 papers, 1.8k citations indexed

About

Daniel Haggstrom is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Daniel Haggstrom has authored 22 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Daniel Haggstrom's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (8 papers) and Cancer therapeutics and mechanisms (4 papers). Daniel Haggstrom is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (8 papers) and Cancer therapeutics and mechanisms (4 papers). Daniel Haggstrom collaborates with scholars based in United States, United Kingdom and France. Daniel Haggstrom's co-authors include Enriqueta Felip, Wu‐Chou Su, James Chih‐Hsin Yang, Myung‐Ju Ahn, David Planchard, Pasi A. Jänne, Mireille Cantarini, Leora Horn, Malcolm Ranson and Serban Ghiorghiu and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Daniel Haggstrom

21 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2015 1.6k citations Pasi A. Jänne, James Chih‐Hsin Yang et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Haggstrom United States	8	1.5k	1.2k	691	455	135	22	1.8k
Adam Płużański Poland	15	1.7k 1.2×	1.6k 1.3×	473 0.7×	319 0.7×	90 0.7×	56	2.1k
Jian Hua Shi China	5	1.6k 1.1×	1.3k 1.1×	462 0.7×	305 0.7×	79 0.6×	6	1.7k
Kathryn H. Brown United Kingdom	15	1.8k 1.2×	1.4k 1.2×	931 1.3×	460 1.0×	169 1.3×	30	2.4k
Nadia Godin-Heymann United States	9	1.1k 0.7×	1.1k 0.9×	957 1.4×	351 0.8×	159 1.2×	10	1.8k
Thanyanan Reungwetwattana Thailand	21	1.4k 0.9×	1.1k 1.0×	571 0.8×	321 0.7×	57 0.4×	72	1.9k
Alessandro Leonetti Italy	18	1.2k 0.8×	1.1k 0.9×	848 1.2×	424 0.9×	97 0.7×	54	2.0k
J. A. Engelman United States	12	1.0k 0.7×	834 0.7×	511 0.7×	257 0.6×	61 0.5×	24	1.3k
Eric Sbar United States	10	1.2k 0.8×	1.1k 0.9×	419 0.6×	239 0.5×	75 0.6×	29	1.5k
Xiuyu Julie Cong United States	13	1.3k 0.9×	1.2k 1.0×	563 0.8×	189 0.4×	104 0.8×	19	1.7k
Chenghua Xia United States	10	843 0.6×	950 0.8×	1.2k 1.8×	468 1.0×	70 0.5×	11	1.9k

Countries citing papers authored by Daniel Haggstrom

Since Specialization

Citations

This map shows the geographic impact of Daniel Haggstrom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Haggstrom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Haggstrom more than expected).

Fields of papers citing papers by Daniel Haggstrom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Haggstrom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Haggstrom. The network helps show where Daniel Haggstrom may publish in the future.

Co-authorship network of co-authors of Daniel Haggstrom

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Haggstrom. A scholar is included among the top collaborators of Daniel Haggstrom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Haggstrom. Daniel Haggstrom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Popat, Sanjay, Benjamin Solomon, Geoffrey Liu, et al.. (2025). Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations

Reinmuth, Niels, Marina Chiara Garassino, Óscar Juan, et al.. (2025). Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology. 43(16_suppl). 8599–8599. 1 indexed citations

Heinzerling, J.H., Kathryn F. Mileham, Myra Robinson, et al.. (2024). Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial. The Lancet Oncology. 26(1). 85–97. 6 indexed citations

Lasheen, Wael, et al.. (2023). Is Karnofsky performance scale a proxy measure of frailty phenotype in older adults with cancer?. Journal of Clinical Oncology. 41(16_suppl). e24035–e24035. 4 indexed citations

Besse, Benjamin, Melissa L. Johnson, S-H.I. Ou, et al.. (2022). 78TiP Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study. Annals of Oncology. 33. S68–S69. 1 indexed citations

Patel, Jai N., et al.. (2020). Identifying potentially inappropriate medication (PIM) use in geriatric oncology. Journal of Geriatric Oncology. 12(1). 34–40. 9 indexed citations

Heinzerling, J.H., Kathryn F. Mileham, Myra Robinson, et al.. (2020). Phase II prospective trial of primary lung tumor stereotactic body radiation therapy (SBRT) followed by concurrent mediastinal chemoradiation and adjuvant immunotherapy for locally-advanced non-small cell lung cancer (NSCLC): Planned toxicity analysis.. Journal of Clinical Oncology. 38(15_suppl). e21047–e21047. 3 indexed citations

Ahn, Eugene R., Pam K. Mangat, Elizabeth Garrett‐Mayer, et al.. (2020). Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 4(4). 757–766. 46 indexed citations

Ahn, Eugene R., Pam K. Mangat, Elizabeth Garrett‐Mayer, et al.. (2019). Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. Journal of Clinical Oncology. 37(15_suppl). 9041–9041. 7 indexed citations

10.

Langer, Corey J., Edward S. Kim, Eric Anderson, et al.. (2018). nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC. Frontiers in Oncology. 8. 262–262. 7 indexed citations

11.

Langer, Corey J., Eric Anderson, Robert M. Jotte, et al.. (2017). ABOUND.70+: Safety and efficacy of nab-paclitaxel/carboplatin (nab-P/C) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 35(15_suppl). 9059–9059. 2 indexed citations

12.

Badin, Firas, Anne C. Chiang, William B. Fisher, et al.. (2016). Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study.. Journal of Clinical Oncology. 34(15_suppl). e20092–e20092. 2 indexed citations

13.

Symanowski, James T., Margaret O. Boltes, Walter F. Ballinger, et al.. (2016). Is There a Role for Stereotactic Biopsy of Unresectable Malignant Brain Lesions? An Analysis of Short-Term Morbidity and Mortality. International Journal of Radiation Oncology*Biology*Physics. 96(2). E103–E103. 1 indexed citations

14.

Hall, Richard D., Tri Minh Le, Daniel Haggstrom, & Ryan D. Gentzler. (2015). Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).. PubMed Central. 4(5). 515–23. 86 indexed citations

15.

Jänne, Pasi A., James Chih‐Hsin Yang, Dong‐Wan Kim, et al.. (2015). AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 372(18). 1689–1699. 1585 indexed citations breakdown →

16.

Burri, Stuart H., Roshan S. Prabhu, Scott D. Wait, et al.. (2015). Is there a role for empiric radiation without a confirmatory biopsy for a subset of patients with radiographically-malignant primary brain tumors?: An analysis of short-term morbidity and mortality.. Journal of Clinical Oncology. 33(15_suppl). e13001–e13001. 1 indexed citations

17.

Mileham, Kathryn F., Qing Zhang, Carol Farhangfar, et al.. (2015). Abstract C80: Development of EGFR C797S mutation in serial liquid biopsy assessments in the clinical practice setting. Molecular Cancer Therapeutics. 14(12_Supplement_2). C80–C80. 1 indexed citations

18.

Heinzerling, J.H., R.J. McCammon, Roshan S. Prabhu, et al.. (2014). Stereotactic Ablative Body Radiosurgery (SABR) in Early-Stage Lung Cancer: Can Results of Advanced Cancer Care in an Innovative De-Centralized Cancer Institute Replicate Favorable Clinical Trial Results?. International Journal of Radiation Oncology*Biology*Physics. 90(1). S613–S614.

19.

Carrizosa, Daniel R., Kathryn F. Mileham, & Daniel Haggstrom. (2013). New targets and new mechanisms in lung cancer.. PubMed. 27(5). 396–404. 3 indexed citations

20.

Baron, Andre T., Jason A. Wilken, Daniel Haggstrom, S. Goodrich, & Nita J. Maihle. (2009). Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.. PubMed. 12(5). 302–8. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact